Life Science REIT Past Earnings Performance
Past criteria checks 0/6
Life Science REIT has been growing earnings at an average annual rate of 21.4%, while the Health Care REITs industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 27% per year.
Key information
21.4%
Earnings growth rate
21.4%
EPS growth rate
| Health Care REITs Industry Growth | 11.2% |
| Revenue growth rate | 27.0% |
| Return on equity | -7.6% |
| Net Margin | -108.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Life Science REIT makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 20 | -22 | 5 | 0 |
| 30 Sep 23 | 20 | -25 | 5 | 0 |
| 30 Jun 23 | 19 | -29 | 5 | 0 |
| 31 Mar 23 | 18 | -28 | 6 | 0 |
| 31 Dec 22 | 16 | -28 | 6 | 0 |
| 31 Dec 21 | 1 | 19 | 2 | 0 |
Quality Earnings: JL6 is currently unprofitable.
Growing Profit Margin: JL6 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if JL6's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare JL6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JL6 is unprofitable, making it difficult to compare its past year earnings growth to the Health Care REITs industry (2.4%).
Return on Equity
High ROE: JL6 has a negative Return on Equity (-7.65%), as it is currently unprofitable.